A novel series of p38 MAP kinase inhibitors for the potential treatment of rheumatoid arthritis

被引：25

作者：

Brown, DS ^{[1
]}

Belfield, AJ ^{[1
]}

Brown, GR ^{[1
]}

Campbell, D ^{[1
]}

Foubister, A ^{[1
]}

Masters, DJ ^{[1
]}

Pike, KG ^{[1
]}

Snelson, WL ^{[1
]}

Wells, SL ^{[1
]}

机构：

[1] AstraZeneca, Macclesfield SK10 4TG, Cheshire, England

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2004年 / 14卷 / 21期

关键词：

p38 MAP kinase inhibitors;

D O I：

10.1016/j.bmcl.2004.08.006

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A novel p38 MAP kinase inhibitor structural class was discovered through selectivity screening. The rational analogue design, synthesis and structure-activity relationship of this series of bisamide inhibitors is reported. The inhibition in vitro of human p38alpha enzyme activity and lipopolysaccharide-induced tumour necrosis factor-alpha release is described for the series. The activity in vivo and pharmacokinetic properties are exemplified for the more potent analogues. (C) 2004 Elsevier Ltd. All rights reserved.

引用

页码：5383 / 5387

页数：5

共 50 条

[1] P38 MAP kinase inhibitors for the treatment of arthritis
Barlocco, D
Langston, S
DRUG DISCOVERY TODAY, 2001, 6 (15) : 808 - 809
[2] Potential of p38 inhibitors in the treatment of rheumatoid arthritis
Foster, ML
Halley, F
Souness, JE
DRUG NEWS & PERSPECTIVES, 2000, 13 (08) : 488 - 497
[3] Does the p38 MAP kinase inhibitor pamapimod have potential for the treatment of rheumatoid arthritis?
Doggrell, Sheila A.
Christensen, Anne-Marie
EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (14) : 2437 - 2442
[4] Design, synthesis, and SAR of a novel series of p38α MAP kinase inhibitors
Martin, Barrie P.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 241
[5] Novel inhibitors of p38 MAP kinase.
Shetty, R
Moffett, KK
Nguyen, D
Kelly, MJ
Michelotti, EL
Dorsey, BD
Springman, E
Bukhtiyarova, M
Northrop, K
Chai, XM
Saporito, MS
Ochman, AR
Karpusas, M
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 228 : U947 - U947
[6] MEDI 370-Design, synthesis and biological activity of a novel series of naphthyridinone derivatives as potent p38α MAP kinase inhibitors for the treatment of rheumatoid arthritis
Yang, Ginger XuQiang
Stelmach, John
Hu, Zao
Koyama, HIroo
Desai, Ranjit C.
Chen, Meng-Hsin
Natarajan, Swaminathan
Miller, Daniel J.
O'Keefe, Stephen
Edward, O'neill
Mitra, Kaushik
Visco, Denise
Owens, Karen
Zaller, Dennis M.
Doherty, Jim B.
Sahoo, Soumya P.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2008, 236
[7] Inhibitors of p38α MAP kinase
Chakravarty, S
ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 37, 2002, 37 : 177 - 186
[8] Potent inhibitors of the map kinase p38
Henry, JR
Rupert, KC
Dodd, JH
Turchi, IJ
Wadsworth, SA
Cavender, DE
Schafer, PH
Siekierka, JJ
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (23) : 3335 - 3340
[9] The development p38 MAP kinase inhibitors
Hynes, John
Wu, H.
Dyckman, A. J.
Lin, S.
Wrobleski, S. T.
Gillooly, K. M.
McIntyre, K. W.
Pitt, S.
Shen, D. R.
Shuster, D. J.
Xia, X.
Zhang, R.
INFLAMMATION RESEARCH, 2007, 56 : S474 - S474
[10] Inhibitors of unactivated p38 MAP kinase
Bullington, James
Argentieri, Dennis
Averill, Kristin
Carter, Demetrius
Cavender, Druie
Fahmy, Bohumila
Fan, Xiaodong
Hall, Daniel
Heintzelman, Geoffrey
Jackson, Paul
Leung, Wai-Ping
Li, Xun
Ling, Ping
Olini, Gilbert
Razler, Thomas
Reuman, Michael
Rupert, Kenneth
Russell, Ronald
Siekierka, John
Wadsworth, Scott
Wolff, Russell
Xiang, Bangping
Zhang, Yue-Mei
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (23) : 6102 - 6106

← 1 2 3 4 5 →